Compounds for the treatment of acute and chronic kidney disease

Patent metadata

Field	Value
Publication number	US-11945781-B2
Application number	US-202318183281-A
Country	US
Kind code	B2
Filing date	Mar 14, 2023
Priority date	Nov 18, 2020
Publication date	Apr 2, 2024
Grant date	Apr 2, 2024

Abstract

The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

First claim

What is claimed is:

1. A compound selected from:

or a pharmaceutically acceptable salt thereof.

2. The compound of claim 1 , wherein the compound is selected from:

and

or a pharmaceutically acceptable salt thereof.

3. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

5. The compound of claim 1 , wherein the compound is selected from:

and

or a pharmaceutically acceptable salt thereof.

6. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

7. The compound of claim 1 , wherein the compound is:

or a pharmaceutically acceptable salt thereof.

8. A pharmaceutical composition comprising a therapeutically effective amount of the compound of claim 1 and a pharmaceutically acceptable carrier.

9. A method for treating a disorder associated with HO-1 signaling dysfunction in a subject in need thereof, the method comprising administering to the subject an effective amount of the compound of claim 1 , wherein the disorder associated with HO-1 signaling dysfunction is a kidney disease.

10. The method of claim 9 , wherein the kidney disease is chronic kidney disease or acute kidney injury (AKI).

11. The method of claim 9 , wherein the effective amount is a therapeutically effective amount.

12. The method of claim 9 , wherein the effective amount is a prophylactically effective amount.

13. The method of claim 9 , wherein the subject is a mammal.

14. The method of claim 13 , wherein the mammal is a human.

15. The method of claim 9 , wherein the subject has been diagnosed with a need for treatment of the disorder prior to the administering step.

16. The method of claim 9 , wherein the subject is at risk for developing the disorder prior to the administering step.

17. The method of claim 9 , further comprising the step of identifying a subject in need of treatment of the disorder.

18. A method for modifying HO-1 signaling in a subject, the method comprising administering to the subject an effective amount of the compound of claim 1 , thereby modifying HO-1 signaling in the subject.

19. The method of claim 18 , wherein modifying is activating.

Assignees

• Southern Res Inst
• Uab Research Foundation
• Us Gov Veterans Affairs

Inventors

• Suto Mark J
• Mathew Bini
• Agarwal Anupam
• Traylor Amie M

Classifications

• A61P13/12

  of the kidneys · CPC title

• C07D215/36 Primary

  Sulfur atoms (C07D215/24 takes precedence) · CPC title

• C07C321/28

  Sulfides, hydropolysulfides, or polysulfides having thio groups bound to carbon atoms of six-membered aromatic rings · CPC title

• C07D213/70

  Sulfur atoms · CPC title

• C07D215/40

  attached in position 8 · CPC title